Background & Aims: Lupoid (LL) and chronic leishmaniais (CCL) are variants of cutaneous leishmaniasis (CL) which are resistant to various treatments. The diseases are endemic in some developing countries such as Iran. A Variety of drugs with different effects have been suggested in recent decades. Carbon deoxide laser has been recently applied in the treatment of different dermatological diseas...

Cutaneous leishmaniasis is a protozoan infectious disease and widespread in Mediterranean basin including Turkey. Lesions usually start with erythematous papules, gradually enlarges and afterwards it ulcerates. We present a 12-year-old boy with diffuse persistent lip swelling mimicking granulomatous cheilitis. Systemic glucantime was started. However, severe hypotension and bradycardia was deve...

The expansion of γδ T cells in patients with active cutaneous leishmaniasis, with or without glucantime therapy, was investigated. Twenty patients with local cutaneous leishmaniasis including glucantime-treated (n=10) and untreated (n=10) patients were selected. The controls were healthy individuals (n=10) living in endemic areas. Whole blood was obtained and the T cell subpopulations were anal...

Pentavalent antimony (SbV) compounds are still considered the first line of treatment for all forms of leishmaniasis. There have been reports of drug resistance and unresponsiveness to treatment with these drugs. We investigated the clinical response to treatment of cutaneous leishmaniasis with glucantime, the drug of choice for all forms of leishmaniasis in Iran. All individuals suspected of c...

Glibenclamide reduced the rate of lesion growth in BALB/c mice infected with Leishmania (Leishmania) mexicana, the effect was dose dependent, and the highest dose proved more effective than glucantime. Cross-resistance to glucantime was found in animals infected with a glibenclamide-resistant line, but combined therapy reduced lesion progression even in the glibenclamide-resistant strain.

A Leishmaniose Tegumentar é uma doença infecciosa negligenciada, endêmica em 13 países da América, tendo o Brasil como responsável por 96% das notificações. O tratamento de primeira linha antimoniato N-metil-glucamina (Glucantime), droga parenteral e com várias contraindicações, que dificulta seu uso regiões isoladas do nosso país, justamente onde a maior incidência ocorre. Em 2020 Ministério S...

Background: The adverse effects and increased resistance of drugs necessities the discovery novel combination therapy. Objectives: This study aimed to examine Artemisinin plus glucantime or shark cartilage extract on Iranian strain Leishmania major (MRHO/IR/75/ER) in vitro vivo. Methods: In experiments, their different concentrations (3.12 - 400 µg/mL) promastigotes, amastigotes, un-infected ma...

In this study we examined enhancement effects of Artemisinin plus Glucantime and shark cartilage extract, on promastigotes and amastigotes of L.infantum in in vitro condition.The toxicity of artemisinin, glucantime and shark cartilage extract on the L. infantum promastigotes and amastigote-infected macrophages was evaluated using MTT assay. The role of these drugs in inducing apoptosis in proma...

The leishmanicidal activity of four batches of meglumine antimoniate, produced in Farmanguinhos-Fiocruz, Brazil (TAMs), was assessed and compared to Glucantime-Aventis Pharma Ltda. Using the amastigote-like in vitro model, the active concentrations of Sb v varied from 10microg/ml to 300microg/ml for L. (L.) chagasi and from 50microg/ml to 300microg/ml for L. (L.) amazonensis, with no statistica...

OBJECTIVES Intralesional injection of pentavalent antimoniate is recommended by the World Health Organization for the treatment of cutaneous leishmaniasis (CL). This study aimed to evaluate the adverse effects of intralesional injection of meglumine antimoniate (Glucantime(®) ) and its influence on clinical laboratory parameters. METHODS A total of 105 patients with suspected lesions and ther...